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Abstract
Aims/hypothesis Changes in cardiac substrate utilisation
leading to altered energy metabolism may underlie the
development of diabetic cardiomyopathy. We studied car-
diomyocyte substrate uptake and utilisation and the role of
the fatty acid translocase CD36 in relation to in vivo cardiac
function in rats fed a high-fat diet (HFD).
Methods Rats were exposed to an HFD or a low-fat diet
(LFD). In vivo cardiac function was monitored by echocar-
diography. Substrate uptake and utilisation were determined
in isolated cardiomyocytes.
Results Feeding an HFD for 8 weeks induced left ventric-
ular dilation in the systolic phase and decreased fractional
shortening and the ejection fraction. Insulin-stimulated
glucose uptake and proline-rich Akt substrate 40 phosphor-
ylation were 41% (p<0.001) and 45% (p<0.05) lower,
respectively, in cardiomyocytes from rats on the HFD.
However, long-chain fatty acid (LCFA) uptake was 1.4-fold
increased (p<0.001) and LCFA esterification into triacyl-
glycerols and phospholipids was increased 1.4- and 1.5-fold,
respectively (both p<0.05), in cardiomyocytes from HFD
compared with LFD hearts. In the presence of the CD36
inhibitor sulfo-N-succinimidyloleate, LCFA uptake and
esterification were similar in LFD and HFD cardiomyocytes.
In HFD hearts CD36 was relocated to the sarcolemma, and
basal phosphorylation of a mediator of CD36-trafficking, i.e.
protein kinase B (PKB/Akt), was increased.
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Abbreviations
ACC acetyl-coenzyme A carboxylase
AMPK AMP kinase
ED end diastole
EDD end diastolic diameter
EDV end diastolic volume
EF ejection fraction
ES end systole
ESD end systolic diameter
ESV end systolic volume
FS fractional shortening
HFD high-fat diet
IVSWT interventricular septum wall thickness
LCFA long-chain fatty acid
LFD low-fat diet
LV left ventricle
PI3K phosphatidylinositol 3′-kinase
PKB/Akt protein kinase B
PPARa peroxisome proliferator activated receptor a
PRAS40 proline-rich Akt substrate 40
PWT posterior wall thickness
SSO sulfo-N-succinimidyloleate
VD left ventricular diameter
Introduction
Diabetic cardiomyopathy (DCM) is a common complica-
tion in type 2 diabetes [1]. Changes in myocardial energy
metabolism, due to altered substrate handling, characterise
diabetes-related heart disease and DCM [1]. Studies in
rodent models, including rats fed a high-fat diet (HFD) [2],
leptin-deficient and -resistant animals [3–6] and transgenic
mice with cardiac-restricted peroxisome proliferator acti-
vated receptor a (PPARa) overexpression [7], indicate that
intramyocardial accumulation of triacylglycerol metabo-
lites (lipotoxicity) and myocardial insulin resistance may
underlie diabetes-related cardiac dysfunction [1, 8].
Among the putative causes of myocardial triacylglycerol
accumulation are elevations in long-chain fatty acid
(LCFA) uptake [6, 7, 9]. In the heart, approximately 50%
of LCFA uptake is mediated by the fatty acid translocase
CD36 [10, 11]. Under physiological conditions, both
insulin and contraction stimulate LCFA uptake by inducing
the translocation of CD36 from an intracellular pool to the
sarcolemma, illustrating that CD36 is also directly involved
in the dynamic utilisation of LCFA by cardiomyocytes.
This acute translocation of CD36 involves activation of
phosphatidylinositol 3′-kinase (PI3K)/protein kinase B
(PKB/Akt)- and AMP-kinase (AMPK)-dependent signal-
ling cascades in response to insulin and contraction,
respectively [11].
Interestingly, CD36 deletion rescues the cardiac dys-
function, metabolic abnormalities and myocardial triacyl-
glycerol accumulation observed in transgenic mice with
cardiac-restricted PPARα overexpression [7], suggesting a
critical role for CD36 in the development of diabetes-
related heart disease [12]. We hypothesised that long-term
alterations in the functional pool of CD36 lead to myo-
cardial accumulation of (toxic) lipid metabolites and insulin
resistance and contribute to the development of diabetes-
related heart disease. To examine this, we first measured in
vivo cardiac dimensions by echocardiography in rats ex-
posed to a high-fat diet (HFD), which impairs myocardial
insulin signalling [2, 13]. Subsequently, isolated cardio-
myocytes were used to determine changes in substrate
uptake and LCFA metabolism under basal conditions and
after incubations with insulin and with oligomycin; the
latter compound induces a contraction-like elevation of
intracellular AMP levels and concomitant activation of
AMPK [14]. Finally, we assessed whether the observed
alterations could be ascribed to CD36 in hearts from rats on
the HFD by analysing the effects of the CD36 inhibitor
sulfo-N-succinimidyloleate (SSO) on myocardial LCFA
uptake and utilisation in isolated cardiomyocytes, and by
studying the expression and subcellular localisation of
CD36 in cardiac ventricular tissue.
Materials and methods
Animals The investigation conformed to the Guide for the
Care and Use of Laboratory Animals published by the
NIH (NIH Publication No. 85-23, revised 1996) and was
approved by the VU University Medical Centre Animal
Care Committee. Adult male Wistar WU rats (n=31;
mean body weight 361±24 g) were purchased from Harlan
CBP (Horst, the Netherlands), and fed an HFD or an
isocaloric low-fat diet (LFD) [2]. At week 8, rats fasted
overnight underwent an OGTT, and post-load blood
glucose levels were determined 15, 30, 60, 90 and
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After 10 weeks on the diet, blood was collected for
determination of glucose and insulin levels. Rats were then
anaesthetised with an intraperitoneal injection of sodium
pentobarbital, and hearts were removed for the isolation of
cardiomyocytes [15].
Diets Experimental diets were obtained from Hope Farms
(Woerden, the Netherlands; HFD, catalogue no. 4148.02;
LFD, catalogue no. 4148.01). The LFD consisted of 8% by
weight of total fat, 22% by weight of protein and 60% by
weight of carbohydrate; the HFD contained 25% by weight
of fat, 32% by weight of protein and 25% by weight of
carbohydrate, as well as more palmitate (91.12 g/kg) and
oleate (100.24 g/kg) compared with the LFD (29.12 and
32.08 g/kg, respectively). In the group fed the HFD, 50.4%
of the ingested calories were derived from fat compared
with 16.4% in the group fed the LFD.
In vivo cardiac function Non-invasive transthoracic echo-
cardiograms were recorded at heart rates of 350–400 beats
per minute in rats anaesthetised with 1.5% isoflurane in a
mixture of N2O/O2 (1/2, vol/vol) [16] before and 8 weeks
after initiation of the diet by an Aloka echo machine
(ProSound SSD-4000) using a 13-MHz linear interfaced
array transducer. M- and B-mode images were obtained in
the parasternal long- and short-axis views of the left ventricle
(LV) at mid-papillary level. At end systole (ES) and end
diastole (ED), LV lumen diameter (D), LV ventricular
diameter (VD) and posterior (PWT) and interventricular
septum (IVSWT) wall thicknesses were determined for three
cardiac cycles andaveraged.The LVdimensionswereusedto
calculate systolic parameters [17]: fractional shortening
FS% ðÞ ¼ ð EDD   ESDÞ=EDDÞ    100% ½ , where EDD is
end diastolic diameter and ESD is end systolic diameter; end
diastolic volume (EDV)=[EDD]
3; end systolic volume
(ESV)=[ESD]
3; and ejection fraction EF% ðÞ ¼ EDV  ð ½
ESVÞ=EDV  100%. LV mass (LVM) was determined
according to the uncorrected cube assumption: 1:05  
EDD þ PWT þ IVS ðÞ
3  EDV
hi
, where 1.05 is the specific
gravity of the myocardium [18].
Plasma and tissue determinations Blood glucose was mea-
sured from tail bleeds using a glucose analyser (HemoCue,
Angelholm, Sweden). Plasma insulin was measured using
ELISA (EZRMI-13K; Linco Research, St Charles, MO,
USA). Myocardial triacylglycerol content was determined in
ventricularlysatesfromaseparatesetofanimalsasdescribed
in [2].
Treatment of isolated cardiomyocytes Cardiomyocytes
were prepared using a Langendorff perfusion system as
described in [15, 19]. Isolated cardiomyocytes were
incubated for 30 min at room temperature with 0.5%
DMSO or SSO [9]. The CD36-specific inhibitor SSO [20]
was used to investigate the involvement of CD36 in basal
LCFA uptake. SSO was applied at a concentration of
0.4 mmol/l, which effectively inhibits CD36 [15, 21].
Then, cells were washed and incubation was continued for
15 min at 37°C with continuous shaking. Thereafter, the
DMSO-treated cardiomyocytes were kept for another
15 min at 37°C and either kept untreated (basal) or
incubated with insulin or oligomycin. To achieve optimal
stimulation of glucose and LCFA uptake [22], insulin and
oligomycin were used at a concentration of 10 nmol/l and
30 μmol/l, respectively. At this concentration, the ATP-
synthase inhibitor oligomycin induces an increase in the
intracellular AMP/ATP ratio, thereby activating AMPK-
mediated signalling pathways without inhibiting oxygen
consumption [14].
Glucose uptake, palmitate uptake and oxidation, and
incorporation into intracellular lipid pools Following
agonist treatment, [
3H]-2-deoxyglucose and [1-
14C] palmi-
tate uptake were simultaneously determined during a 3-min
incubation [15]. Rates of [1-
14C] palmitate oxidation
(measured as the production of
14CO2) and esterification
(measured as incorporation of the
14C label into intracellu-
lar phospholipids [PL], and triacylglycerol) were deter-
mined after a 20-min incubation [9].
Western blotting Phosphorylation of proline-rich Akt-
substrate 40 (PRAS40-Thr246) and acetyl-coenzyme A
carboxylase-Ser79 (ACC-Ser79) was determined in homog-
enates of cardiomyocytes by western blotting using phos-
pho-specific antibodies [9, 13]. PKB/Akt-Ser473
phosphorylation was determined in ventricular homogenates
as described in [2]. Expression levels of CD36 were
determined by western blotting using the monoclonal
CD36 MO25 antibody [23]. Immunoblots were quantified
by densitometric analysis of the films [2].
Cardiac morphology and subcellular localisation of CD36 Car-
diac ventricular tissue collected in a previous study [2] was
routinely embedded in paraffin (Histowax; Leica Micro-
systems, Wetzlar, Germany). Sections (5 μm) were cut, and
mounted on slides coated with 3-aminopropyltriethoxisi-
lane (Menzal, Darmstadt, Germany). After deparaffinisation
and rehydration, the slides were used for determination of
cardiomyocyte cross-sectional area or immunohistochemi-
cal staining of CD36.
Cross-sectional area was determined in randomly chosen
fields in haematoxylin/eosin-stained slides using NIH
image analysis software (National Institutes of Health,
Bethesda, MD, USA) for 20–30 cells per heart and
normalised to sarcomere length [24].
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with Tris-buffered saline (TBS; 50 mmol/l Tris–Cl,
500 mmol/l NaCl, pH 7.6), and incubated overnight with
the monoclonal CD36 MO25 antibody [23] diluted 1:2,000
in TBS containing 0.5% Triton X-100, pH 7.6 at 4°C. After
several washes in TBS, sections were incubated for 1.5 h at
room temperature with biotinylated anti-mouse IgG (Vector
Laboratories, Burlingame, CA, USA), diluted 1:250 in
TBS, followed by incubation for 1 h at room temperature
with avidin–biotin–peroxidase (1:400; ABC Elite kit;
Vector Laboratories). Tissue-bound peroxidase was visual-
ised with the 3,3′-diaminobenzidine tetrahydrochloride
(DAB) chromogen reaction (7.5 mg DAB, 5 μl
30% H2O2 in 15 ml 50 mmol/l Tris–Cl, pH 7.6) for
10 min at room temperature. Sections were then rinsed with
distilled water, dehydrated in a graded series of ethanol,
cleared in xylene, and coverslipped with Entellan (Merck,
Darmstadt, Germany). Sections were analysed using a
Leica DM-LB light microscope (Leica, Rijswijk, the
Netherlands). Digital images were taken at ×200 magnifi-
cation using a Leica DC500 digital camera, and quantified
using Quantity One software (Bio-Rad Laboratories,
Veenendaal, the Netherlands).
Statistical analysis Unless indicated otherwise, data are
expressed as means±SE for the indicated number of
animals (n). Statistical analysis was performed in SPSS
for Mac OS X version 11.0.4 (SPSS Inc., Chicago, IL,
USA). Differences between the LFD and HFD groups were
determined using independent t tests. The paired sample t
test was used to define the effect of agonist incubations on
cardiomyocyte preparations. p<0.05 was considered as
statistically significant.
Results
HFD induces cardiac contractile dysfunction Feeding rats
isocaloric LFD or HFD diets for 8 weeks induced similar
weight gains in the two groups (Table 1), but mild glucose
intolerance, as determined by an oGTT, in HFD- vs LFD-rats
(p<0.05; Fig. 1a). Figure 1b shows the LV dimensions at the
start and 8 weeks after initiation of the diet interventions.
Baseline parameters were similar in the two groups (Table 1).
After 8 weeks on the diet, LVM, ED-VD, EDD and ED-
IVSWT showed comparable increases in LFD and HFD
hearts (all p<0.05), whereas ED-PWT was unaffected by the
diet (Table 1). In the ES phase, both ES-PWT and ES-
IVSWT were increased in LFD hearts only (both p<0.005;
Table 1). ES-VD was similarly affected by LFD and HFD
feeding. ESD was increased in LV from HFD-fed vs LFD-
fed rats (p<0.01;Table1). FS% was increased in LFD hearts
(p<0.05), and decreased in HFD hearts during the course of
the diet intervention (p<0.02; Table 1). Accordingly, EF%
was decreased in HFD compared with LFD hearts (p<0.05;
Table 1). Collectively, these data show that HFD induced
cardiac contractile dysfunction in rats.
Insulin action, but not AMPK signalling, is impaired in HFD
cardiomyocytes We used cardiomyocytes to unravel the
diet-induced molecular alter a t i o n si ne n e r g ys u b s t r a t e
uptake and intracellular signalling pathways. Cardiomyo-
cytes were isolated from a separate group of rats, fed either
the LFD or the HFD under identical experimental con-
ditions. At killing, body, heart and liver weights were
similar between LFD- and HFD-fed rats, whereas perirenal
fat pad weight was 50% higher in HFD- than in LFD-fed
rats (p<0.001; Table 2). Furthermore, HFD feeding
increased blood glucose levels (p<0.02) and lowered
plasma insulin levels (p<0.05).
Basal 2-deoxyglucose glucose uptake rates were 7.3±0.8
and 11.0±1.6 nmol min
−1 [g wet cell mass]
-1C in LFD and
HFD cells, respectively (p=0.063; Fig. 2). Insulin stimu-
lated 2-deoxyglucose uptake 3.7-fold in LFD cardiomyo-
cytes and 2.2-fold in HFD cardiomyocytes (both p<0.001
vs basal, p<0.02 HFD vs LFD), indicating reduced
myocardial insulin responsiveness. Oligomycin had similar
stimulatory effects on 2-deoxyglucose uptake in HFD and
LFD cardiomyocytes (HFD, 1.6-fold stimulation; LFD, 1.7-
fold stimulation; both p<0.05 vs basal).
Activation of phosphatidylinositol 3′-kinase (PI3K)/
protein kinase B (PKB/Akt)- and AMP-kinase (AMPK)-
Table 1 In vivo cardiac characteristics of rats before and after
8 weeks on an HFD or a LFD
Start LFD HFD
(n=24) (n=8) (n=16)
Physiological parameters
Body weight (g) 295±4 476±8* 463±8*
Left ventricular mass (mg) 637±15 890±18* 882±32*
LV diastolic parameters
Posterior wall thickness (mm) 1.63±0.03 1.80±0.07 1.71±0.05
Lumen diameter (mm) 6.92±0.07 7.55±0.20* 7.68±0.10*
Interventricular septum
wall thickness (mm)
1.37±0.03 1.67±0.08* 1.54±0.04*
Ventricular diameter (mm) 9.80±0.06 10.86±0.13* 10.89±0.12*
LV systolic parameters
Posterior wall thickness (mm) 2.93±0.06 3.45±0.12* 3.00±0.08**
Lumen diameter (mm) 3.41±0.10 3.32±0.25 4.07±0.12*
,**
Interventricular septum
wall thickness (mm)
2.51±0.05 2.85±0.09* 2.67±0.06
Ventricular diameter (mm) 8.81±0.07 9.82±0.12* 9.81±0.10*
Fractional shortening (%) 50.8±1.3 56.3±2.4* 47.1±1.7*
,**
Ejection fraction (%) 87.5±1.0 91.1±1.4 84.9±1.0*
,**
Data are means±SE
*p<0.05 vs start
**p<0.01 vs LFD
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stimulation of glucose uptake in response to insulin and
oligomycin, respectively. We studied whether changes in
the activation of these signalling pathways paralleled the
observed alterations in glucose uptake rates in HFD cells.
Therefore, phosphorylation of PRAS40-Thr246 and ACC-
Ser79 were examined as respective distal determinants for
PKB/Akt and AMPK activity [13, 25], as the presence of
bovine serum albumin (mol. mass 66 kDa) in the
cardiomyocyte homogenates interfered with direct mea-
surement of PKB/Akt (mol. mass 64 kDa) and AMPKα
phosphorylation (mol. mass 62 kDa). Basal PRAS40-Thr246
phosphorylation was 1.7-fold higher in HFD than in LFD
cells (p<0.05;Fig.3a,b). Insulin stimulated PRAS40-Thr246
phosphorylation 12.0-fold in LFD cells (p<0.001) and 4.0-
fold in HFD cells (p<0.001), thus confirming reduced
insulin responsiveness. Oligomycin did not affect PRAS40-
Thr246 phosphorylation.
ACC-Ser79 phosphorylation was measured as a deter-
minant of AMPK activity [25]. Basal levels of Ser79-
phosphorylated ACC were similar in LFD and HFD cells
(Fig. 3c,d). Insulin had no effect on ACC-Ser79 phosphor-
ylation, whereas oligomycin stimulated ACC-Ser79 phos-
phorylation in LFD and HFD cells to a similar extent
(HFD, 3.0-fold stimulation; LFD, 2.9-fold stimulation; both
p<0.001 vs basal), indicating that AMPK signalling was
not affected by high-fat feeding.
HFD feeding results in increased CD36-mediated LCFA
uptake Basal rates of LCFA uptake were increased 1.4-fold
(p<0.001) in HFD compared with LFD cells (Fig. 4). The
CD36 inhibitor SSO reduced basal LCFA uptake by 44%
(p<0.001) and 23% (p<0.05) in HFD and LFD cardio-
myocytes, respectively. Notably, the absolute rates of LCFA
uptake were similar between SSO-treated LFD and HFD
cells (Fig. 4), suggesting that the increased basal LCFA
uptake rates in HFD cells can be ascribed to changes in the
sarcolemmal pool of CD36. Insulin stimulated LCFA
uptake 1.3-fold in LFD cells (p<0.02 vs basal) but had no
effect in HFD cells (p<0.02 vs LFD; Fig. 4). Oligomycin
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Fig. 1 a Blood glucose levels after an oral glucose load in rats fed the HFD (closed circles; n=16) and the LFD (open circles; n=8). Data are means±SE.
b Representative echocardiographic M-mode images from at least three cardiac contractile cycles at the start of the diet intervention and 8 weeks after
initiation of the LFD and HFD, respectively
Table 2 Characteristics of rats after 10 weeks on a high- or low-fat
diet
LFD HFD
(n=14) (n=17)
Body composition
Body weight at killing (g) 465±5 472±10
Heart weight (% body weight) 0.445±0.007 0.431±0.012
Liver weight (% body weight) 3.10±0.07 3.02±0.08
Perirenal fat pad weight
(% body weight)
1.63±0.08 2.43±0.14*
Plasma characteristics
Blood glucose (mmol/l) 5.50±0.08 5.78±0.08**
Plasma insulin (pmol/l) 269±18 216±16***
Data are means±SE
*p<0.001 vs LFD
**p<0.02 vs LFD
***p<0.05 vs LFD
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Fig. 2 Rates of 2-deoxyglucose uptake in cardiomyocytes from rats
fed the LFD (open bars) and the HFD (filled bars). Cardiomyocytes
were incubated with DMSO (Basal), insulin (INS) or oligomycin (Oli)
before measurement of 2-deoxyglucose uptake. Data are expressed as
wet cell mass and are means±SE; n=8. *p<0.02, agonist effect; #p<
0.02, diet effect
1942 Diabetologia (2007) 50:1938–1948increased LCFA uptake in LFD and HFD cardiomyocytes
to the same extent (Fig. 4; both p<0.05 vs basal).
We next examined the metabolic fate of LCFA following
their uptake by HFD and LFD cardiomyocytes. Basal rates
of LCFA oxidation were reduced by 22% in HFD relative
to LFD cells (Fig. 4b; p<0.01). SSO further lowered
cardiomyocyte LCFA oxidation rates by 66% (p<0.005)
and 31% (p<0.05) in LFD and HFD cells, respectively, but
absolute rates of LCFA oxidation were comparable in SSO-
treated LFD and HFD cells.
The incorporation rate of LCFA into triacylglycerol was
increased 1.4-fold (p<0.05) in HFD compared with LFD
cells under basal conditions (Fig. 4c). SSO reduced
triacylglycerol formation in both LFD and HFD cells (both
p<0.05 vs basal). Notably, the absolute triacylglycerol
esterification rates in SSO-treated cells did not differ
between HFD- and LFD-fed rats. Also, the incorporation
of LCFA into phospholipids under basal conditions was
increased 1.5-fold in HFD vs LFD cells (p<0.05; Fig. 4c),
and was reduced by SSO in both LFD and HFD cells (both
p<0.05 vs basal). Myocardial triacylglycerol content was
181±50 μg/mg protein in LFD rats and 330±114 μg/mg
protein in HFD rats (p<0.02) [2].
HFD induces cardiomyocyte hypertrophy and alters the
subcellular localisation of CD36 The inhibitory effect of
SSO suggests that the increased basal LCFA uptake and
esterification rates in HFD cells can be ascribed to changes
in the sarcolemmal pool of CD36. Western blot analysis
indicated that the levels of CD36 were similar between
HFD and LFD hearts (Fig. 5a). Immunohistochemical
staining of cardiac LV tissue indicated cardiomyocyte
hypertrophy, as reflected by an increased cross-sectional
area (p<0.05 vs LFD; Table 3), and showed a more
abundant presence of CD36 at the sarcolemmal membrane,
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Fig. 4 Rates of palmitate uptake (a), oxidation (b) and esterification
into intracellular triacylglycerols and phospholipids (c) in cardiomyo-
cytes from LFD-fed rats (open bars) and HFD-fed rats (filled bars).
Cardiomyocytes were incubated with DMSO (Basal), insulin (INS),
oligomycin (Oli) or SSO before measurement of palmitate uptake.
Data are wet cell mass and are means±SE; n=8. *p<0.05, agonist
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Diabetologia (2007) 50:1938–1948 1943particularly at the intercalated discs, in HFD hearts compared
with LFD hearts (p<0.002 vs LFD; Fig. 5b,c and Table 3).
As insulin stimulated LCFA uptake in isolated cardio-
myocytes (Fig. 4), we also examined the subcellular local-
isation of CD36 in hearts isolated 30 min following an
intraperitoneal injection with insulin (10 U/kg body weight)
[2]. Figure 5d shows that in vivo insulin treatment increased
CD36 immunoreactivity at the intercalated discs in LFD
hearts (p<0.01 vs saline; Table 3). In HFD hearts, insulin
did not further recruit CD36 to the sarcolemma (Fig. 5e).
HFD-induced CD36 redistribution to the sarcolemma
precedes the onset of cardiac contractile dysfunction and
associates with elevated basal phosphorylation of PKB/
Akt We next analysed whether HFD-induced alterations in
CD36 localisation precede the onset of cardiac contractile
dysfunction, using rats fed an LFD or HFD for 4 weeks.
This period was chosen based on serial echocardiographic
measurements, which revealed a tendency towards de-
creased cardiac contractile function 4 weeks after initiation
of the diet intervention. Specifically, FS% was 4.2% lower
(p=0.07) and EF% was 3.3% lower (p=0.10) in HFD vs
LFD hearts after 4 weeks on the diet (data not shown),
compared with the 9.2 and 6.2% decreases observed after
8 weeks of the feeding regime (both p<0.05; Table 1).
Despite the absence of significant effects on cardiac function
after 4 weeks of HFD feeding, immunohistochemical
staining of cardiac LV tissue showed that the abundance of
CD36 at the sarcolemmal membrane was already markedly
increased (Fig. 6a,b) to levels almost similar to those
observed after 8 weeks of HFD feeding (Fig. 5b,c).
Finally, we analysed whether HFD feeding induced
changes in the activity of signalling pathways implicated
in CD36 trafficking. In the healthy myocardium, CD36 is
stored in at least two endosomal storage pools that are
regulated by AMPK and PKB/Akt, respectively [26]. As
insulin does not further recruit CD36 to the sarcolemma in
HFD hearts (Fig. 5e), we proposed that increases in basal
activity of PKB/Akt may underlie the redistribution of
CD36 in HFD hearts. Phosphorylation of PKB/Akt was
determined in LV homogenates of the same group of saline-
injected rats in which CD36 localisation was measured. As
shown in Fig. 6c,d, basal phosphorylation of PKB/Akt was
1.7- and 2.6-fold higher after 4 and 8 weeks of HFD feed-
ing, respectively (both p<0.05). Collectively, these results
indicate that increased activity of PKB/Akt may underlie
CD36 redistribution to the sarcolemma, and that these
events precede the LV dysfunction induced by HFD feeding.
Discussion
Here we report that HFD feeding induces cardiac contrac-
tile dysfunction in rats and that this is associated with a
permanent relocation of CD36 to the sarcolemma. The
continuous presence of CD36 at the sarcolemmal mem-
Anti-CD36
HFD LFD
a
Fig. 5 Expression and subcellular localisation of CD36. Expression of
CD36 in ventricular lysates of HFD and LFD rats. Ponceau S staining
confirmed that the filters contained equal amounts of ventricular
extracts (a). Immunohistochemical staining for CD36 localisation of
cardiac LV tissue sections from rats fed an LFD (b, d) or HFD (c, e) for
8 weeks. Rats received an i.p. injection of saline (b, c) or insulin (d, e)
30 min before killing. Photographs are representative of two indepen-
dent experiments performed on three rats per experimental group.
Arrows indicate intercalated discs. Scale bar indicates 25 μm
Table 3 Cardiac morphology and subcellular localisation of CD36
LFD HFD
(n=6) (n=8)
Morphology
Cardiomyocyte cross-sectional area
normalised to sarcomere length (μm
2)
214±3.5 276±23*
CD36 localisation
Sarcolemma
Saline (%) 61.7±3 74.8±1**
Insulin (%) 75.9±4*** 78.2±3
Cytoplasm
Saline (%) 38.3±3 25.2±1**
Insulin (%) 24.1±4*** 21.8±3
Data are means±SE
*p<0.05 vs LFD
**p<0.002 vs LFD
***p<0.01 vs saline
1944 Diabetologia (2007) 50:1938–1948brane results in enhanced rates of LCFA uptake and sub-
sequent esterification. We propose that this contributes to a
decrease in myocardial insulin action and the development
of diabetes-related heart disease. In addition, we show that
AMPK-mediated responses are not affected by the compo-
sition of the diet.
A key observation in this study is that the alterations in
cardiac contractile function in HFD hearts was associated
with a continuous presence of CD36 at the sarcolemmal
membrane. The present study provides the first morpho-
logical evidence for translocation of CD36 to the sarco-
lemmal membrane. Importantly, the amount of sarcolemmal
CD36 closely correlated with enhanced LCFA uptake rates
in isolated cardiomyocytes. The observation that SSO
inhibited LCFA uptake in HFD cardiomyocytes to the
same residual levels as measured in LFD cardiomyocytes
provides further pharmacological evidence that the en-
hanced flux of LCFA in the heart of HFD-fed rats is a direct
consequence of the relocalisation of CD36 to the sarcolem-
mal membrane.
Previously, a redistribution of CD36 to both subsarco-
lemmal and intramyofibrillar mitochondria has also been
observed [27, 28]. Can the observed CD36 immunoreac-
tivity be ascribed to subsarcolemmal mitochondria rather
that the sarcolemma itself? Stimuli inducing translocation
of CD36 to the mitochondria are expected not to discrim-
inate between the subsarcolemmal and the intramyofibrillar
mitochondria. Hence, if a stimulus or condition, in this case
insulin or HFD feeding, were to increase the subsarcolem-
mal CD36 content, one would expect a similar increase in
intramyofibrillar CD36 content. This, however, could not
be confirmed in the immunohistochemical experiments.
Furthermore, biochemical fractionations performed in pre-
vious studies substantiate the idea that a significant fraction
of CD36 is present at the sarcolemma of hearts from
insulin-resistant rats, and that only a minor portion of CD36
is found within the mitochondrial fractions [9, 22]. While
insulin has been shown to translocate CD36 to the
sarcolemma [9, 22], insulin-mediated CD36 translocation
to the mitochondria has never been reported and even
seems counterintuitive. Collectively, the available evidence
strongly supports the idea that the observed CD36 im-
munoreactivity can be ascribed to CD36 located at the
sarcolemma rather than in subsarcolemmal mitochondria.
The combined data of this and our earlier study on obese
Zucker rats [9] suggest that relocalisation of CD36 is a
general phenomenon in insulin-resistant hearts, and raises
the question of what mechanism underlies the continuous
presence of CD36 at the sarcolemmal membrane in HFD
hearts. In the healthy myocardium, CD36 is stored in at
least two endosomal storage pools that are regulated by
AMPK and PI3K/PKB/Akt, respectively [26]. Activation of
AMPK is critical for contraction- and oligomycin-mediated
CD36 translocation, whereas PI3K/PKB/Akt is critical for
insulin-mediated CD36 trafficking [10, 14, 26]. Basal
phosphorylation of PKB/Akt and its distal target, PRAS40,
were elevated in HFD compared with LFD hearts, whereas
AMPK activity was not affected by the diet. Furthermore,in
cells from HFD-fed rats, the stimulatory effects of insulin on
LCFA uptake, CD36 translocation and phosphorylation of
PKB/Akt and PRAS40 were abrogated, whereas oligomycin-
d
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Fig. 6 Effect of the duration of HFD feeding on CD36 localisation and
phosphorylation of PKB/Akt. Immunohistochemical staining for CD36
localisation of cardiac LV tissue sections from saline-injected rats fed
an LFD (a) or HFD (b) for 4 weeks. Photographs are representative of
two or three independent experiments performed on six rats per
experimental group. The arrows indicate intercalated discs. The scale
bar indicates 25 μm. c Immunoblot and quantification d of PKB/Akt-
Ser473 phosphorylation levels in ventricular homogenates from saline-
injected rats fed an LFD (open bars) or HFD (filled bars)f o r4a n d
8 weeks, respectively. Data are means±SE, n=8. *p<0.05, diet effect
Diabetologia (2007) 50:1938–1948 1945induced AMPK activation and LCFA uptake was unimpaired
between cardiomyocytes from LFD- and HFD-fed rats.
Although we cannot exclude a contribution of other kinases
or HFD-induced alterations in the as yet undisclosed
trafficking machinery regulating the internalisation of CD36
[11, 26], our observations do not argue against the
suggestion that increases in PKB/Akt activity may contribute
to the sustained sarcolemmal presence of CD36 in the heart
of HFD-fed rats.
Previously, we suggested that increased plasma insulin
might contribute to CD36 relocalisation in hearts from
obese Zucker rats [9]. As systemic hyperinsulinaemia was
not observed in HFD-fed rats [2, 13], it remains interesting
to examine whether changes in the activity of other
(insulin-independent) regulators of PKB/Akt phosphoryla-
tion, such as PI3Kγ- and β2-adrenergic receptor signalling
pathways, Ca
2+-calmodulin dependent kinase, protein
phosphatase 2A and the sympathetic nervous system [29],
can be linked to the observed increase in PKB/Akt phos-
phorylation in HFD hearts.
The metabolic and biochemical data were paralleled by
in vivo cardiac functional changes. Importantly, HFD-
induced cardiac contractile dysfunction does not seem to
be linked to diet-related elevations in blood pressure. Cir-
cadian haemodynamic parameters were monitored using
implanted telemetry devices in an experiment performed in
a separate group of animals. We found a slight increase in
night-time (activity-related) heart rate in HFD rats, but no
changes in blood pressure even after 10 weeks of exposure
to the diet (Electronic supplementary material Table 1).
Others confirmed the absence of relevant hypertension after
feeding rats a diet containing 74% fat for 17 weeks [30].
This underscores the possibility that alterations in metabo-
lism, rather than in haemodynamics, underlie the impair-
ment in cardiac contractile function in HFD rats.
The present study also suggests that HFD-induced
alterations in the functional pool of CD36 may contribute
to an imbalance in LCFA uptake and in oxidation and ester-
ification rates in HFD vs LFD cells. Whereas LCFA uptake
rates were increased 1.4-fold in HFD cells, the LCFA
oxidation rates were not increased but rather modestly lower
in HFD cells, while the rates of esterification into triacyl-
glycerol and phospholipids were 1.4-fold higher in HFD vs
LFD cardiomyocytes. Accordingly, triacylglycerol content
was 1.9-fold increased in HFD compared with LFD hearts
[2]. It seems unlikely that changes in malonylCoA levels
underlie the reduced rates of LCFA oxidation in HFD hearts,
as no diet-induced changes in ACC phosphorylation were
found. Rather, degenerative changes in mitochondria, such
as matrix dilution, cristolysis and mitochondria-associated
lamellar bodies, have been observed in cardiomyocytes from
HFD-fed rats [2] and have been linked to reduced oxidative
capacity and lipid accumulation in skeletal muscle from
patients with type 2 diabetes. However, further studies are
required to examine whether these changes contribute to the
reduced basal LCFA oxidation and increased LCFA esteri-
fication rates, or whether the extra LCFA taken up by HFD
cells are stored as triacylglycerol and phospholipids as a
consequence of HFD-induced changes in enzymes promot-
ing LCFA esterification or inhibition of lipolysis.
An important finding of this study is that the HFD-
induced CD36 redistribution preceded the onset of cardiac
contractile dysfunction. Although we cannot unequivocally
link CD36 redistribution to cardiac dysfunction, a recent
report provided strong support for this notion as the
absence of CD36 was found to prevent myocardial tria-
cylglycerol accumulation in transgenic mice with cardiac
PPARα overexpression, both under normal conditions and
after HFD feeding [12]. Similarly, alterations in PKB/Akt
activity have been linked to cardiac dysfunction [31].
Myocardial biopsy samples obtained from patients with
advanced heart failure or dilated cardiomyopathy show
increased basal phosphorylation of PKB/Akt [32, 33], and
transgenic mouse models with constitutively activated
PKB/Akt in the heart develop hypertrophy, decreased
cardiac function and impaired recovery from ischaemia–
reperfusion injury [31, 34]. Whereas chronic activation of
PKB/Akt increases basal glucose uptake rates in the heart
[35], the effects on myocardial lipid metabolism have not
been studied. Interestingly, PKB/Akt signalling has been
linked to palmitate-induced beta cell lipotoxicity [36].
Based on this report and the findings described in this
study, it would be of interest to analyse animals expressing
chronically active PKB/Akt for translocation of CD36 to
the sarcolemma and myocardial lipid accumulation.
It seems plausible that an enhanced CD36-mediated
LCFA uptake rate may contribute to the development of
cardiac contractile dysfunction. An increased supply of
LCFA may influence excitation–contraction coupling as
well as other processes linked to cellular Ca
2+ handling [37,
38]. Furthermore, triacylglycerol accumulation is strongly
linked to cardiac insulin resistance and contractile dysfunc-
tion [1, 2, 8]. The dynamic equilibrium between triacylgly-
cerol stores and triacylglycerol metabolites causes
accumulation of ceramide and diacylglycerol during pro-
longed LCFA influx. Both ceramide and diacylglycerol
have been implicated in the activation of serine/threonine
kinases, such as PKC, Jun N terminal kinase (JNK), and
inhibitor of nuclear factor-κB kinase (IKK), which coun-
teract insulin signalling [39, 40]. Notably, chronic myocar-
dial activation of Akt in transgenic mice has also been
linked to feedback inhibition of PI3K activity [33] and
blunted insulin stimulation of glucose uptake [35]. Impor-
tantly, reduced insulin responsiveness reduces the ability of
insulin to regulate substrate handling, e.g. metabolic
inflexibility [41]. In this study and previous reports [2,
1946 Diabetologia (2007) 50:1938–194813], we show that HFD feeding reduces insulin respon-
siveness and impairs metabolic flexibility, as illustrated by
the blunted effects of insulin on the stimulation of glucose
uptake, phosphorylation of PRAS40, LCFA uptake and
translocation of CD36 to the sarcolemma.
We conclude that HFD feeding in rats induces cardiac
contractile dysfunction, which is preceded by relocation of
CD36 to the sarcolemma, and elevated basal levels of
phosphorylated PKB/Akt.The continuous presence of CD36
at the sarcolemma contributes to enhanced rates of fatty
acid uptake, resulting in myocardial triacylglycerol accu-
mulation and accompanying insulin resistance. Collective-
ly, these data suggest that alterations in the subcellular
localisation of CD36 may contribute to the development of
diabetes-related heart disease and that CD36 may be a
therapeutic target to prevent cardiac dysfunction and the
development of heart failure in diabetes.
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